[go: up one dir, main page]

EA200700312A1 - Композиции для доставки лекарственных средств с высокой водорастворимостью - Google Patents

Композиции для доставки лекарственных средств с высокой водорастворимостью

Info

Publication number
EA200700312A1
EA200700312A1 EA200700312A EA200700312A EA200700312A1 EA 200700312 A1 EA200700312 A1 EA 200700312A1 EA 200700312 A EA200700312 A EA 200700312A EA 200700312 A EA200700312 A EA 200700312A EA 200700312 A1 EA200700312 A1 EA 200700312A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
delivery
water solubility
high water
medicines
Prior art date
Application number
EA200700312A
Other languages
English (en)
Other versions
EA012522B1 (ru
Inventor
Эндрю Сянь Чэнь
Original Assignee
ЭсДи ФАРМАСЬЮТИКАЛЗ, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭсДи ФАРМАСЬЮТИКАЛЗ, ИНК. filed Critical ЭсДи ФАРМАСЬЮТИКАЛЗ, ИНК.
Publication of EA200700312A1 publication Critical patent/EA200700312A1/ru
Publication of EA012522B1 publication Critical patent/EA012522B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение включает композиции для доставки лекарственных средств с высокой водорастворимостью (таких как алкалоиды барвинка) и способы применения таких композиций.
EA200700312A 2004-07-12 2005-07-12 Композиции для доставки лекарственных средств с высокой водорастворимостью (варианты) и их применение в лечении злокачественной опухоли EA012522B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/889,226 US7871632B2 (en) 2004-07-12 2004-07-12 Compositions for delivering highly water soluble drugs
PCT/US2005/024594 WO2006017246A2 (en) 2004-07-12 2005-07-12 Compositions for delivering highly water soluble drugs

Publications (2)

Publication Number Publication Date
EA200700312A1 true EA200700312A1 (ru) 2007-08-31
EA012522B1 EA012522B1 (ru) 2009-10-30

Family

ID=35541622

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700312A EA012522B1 (ru) 2004-07-12 2005-07-12 Композиции для доставки лекарственных средств с высокой водорастворимостью (варианты) и их применение в лечении злокачественной опухоли

Country Status (18)

Country Link
US (4) US7871632B2 (ru)
EP (1) EP1773294A4 (ru)
JP (1) JP4643641B2 (ru)
KR (1) KR20070032816A (ru)
CN (1) CN1859898B (ru)
AU (1) AU2005271873A1 (ru)
BR (1) BRPI0513178A (ru)
CA (1) CA2578574C (ru)
EA (1) EA012522B1 (ru)
EC (1) ECSP077238A (ru)
IL (1) IL180350A0 (ru)
MA (1) MA29662B1 (ru)
MX (1) MX2007000416A (ru)
NO (1) NO20070785L (ru)
RS (1) RS20070029A (ru)
TW (1) TW200607525A (ru)
WO (1) WO2006017246A2 (ru)
ZA (1) ZA200701167B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007107359A (ru) * 2004-07-28 2008-09-10 ЭсДи ФАРМАСЬЮТИКАЛЗ, ИНК. (US) Стабильная инъецируемая композиция альфа-токоферилсукцината, его аналогов и солей
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
CN101011355B (zh) * 2006-02-01 2013-01-02 陈献 经维生素e琥珀酸酯稳定的医药组合物、其制备及用途
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2007133711A2 (en) * 2006-05-12 2007-11-22 Adventrx Pharmaceuticals, Inc. Pharmaceutical compositions for vein irritating drugs
WO2009078756A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078754A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
US8618056B2 (en) * 2007-12-22 2013-12-31 Cuthbert O. Simpkins Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US8063020B2 (en) * 2007-12-22 2011-11-22 Simpkins Cuthbert O Resuscitation fluid
US8906855B2 (en) * 2007-12-22 2014-12-09 Vivacelle Bio, Inc. Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
EP2254554A1 (en) * 2008-02-25 2010-12-01 Novavax, Inc. Sugar glassified virus like particles (vlps)
US20090286832A1 (en) * 2008-05-15 2009-11-19 Kiichiro Nabeta Narcotic emulsion formulations for treatment of surgical pain
KR101564058B1 (ko) * 2009-02-26 2015-10-29 테이코쿠 팔마 유에스에이, 인코포레이티드 암 통증 치료용 마취 유상액 제제
CN101879138A (zh) 2009-05-06 2010-11-10 上海恒瑞医药有限公司 长春花生物碱纳米乳剂注射液及其制备方法
JP5860399B2 (ja) * 2009-08-14 2016-02-16 オプコ ヘルス， インコーポレイテッド ニューロキニン−１アンタゴニストの静脈内用製剤
MX354575B (es) * 2010-10-22 2018-03-12 Dr Reddys Laboratories Inc Uso de depósito de fosfolípidos viscosos estables en almacenamiento para tratar heridas..
WO2012135856A2 (en) * 2011-04-01 2012-10-04 Spectrum Pharmaceuticals, Inc. Very low dose vinorelbine for treatment of cancer
CN102743337B (zh) * 2011-04-20 2014-04-16 国家纳米科学中心 一种纳米粒子药物组合物及其制备方法
WO2012170796A1 (en) * 2011-06-09 2012-12-13 Amylin Pharmaceuticals, Inc. Gel compositions
EP2770980A4 (en) * 2011-10-25 2015-11-04 Univ British Columbia LOW SIZE LIPID NANOPARTICLES AND METHODS THEREOF
RU2664700C2 (ru) 2012-05-10 2018-08-21 Пейнреформ Лтд. Депо-составы местного анестетика и способы их получения
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
EP2971013B1 (en) 2013-03-15 2020-08-19 The University Of British Columbia Lipid nanoparticles for transfection and related methods
US20160290093A1 (en) * 2015-04-02 2016-10-06 Baker Hughes Incorporated Disintegrating Compression Set Plug with Short Mandrel
CN108348581B (zh) 2015-09-04 2022-07-01 斯克利普斯研究所 胰岛素免疫球蛋白融合蛋白
WO2022107843A1 (ja) * 2020-11-19 2022-05-27 日本化薬株式会社 血管障害を発症する水溶性薬含有組成物、血管障害を発症する水溶性薬含有投与液調製用溶液、キット、血管障害抑制剤、及びノニオン型界面活性剤含有溶液
US12419850B1 (en) 2024-03-21 2025-09-23 GanD, Inc. Bioactive fluid compositions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US224042A (en) * 1880-02-03 Music-rest for piano-fortes
US670001A (en) * 1900-02-15 1901-03-19 Stephen B Morss Combined curb and gutter.
US4816247A (en) * 1985-09-11 1989-03-28 American Cyanamid Company Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs
IL88076A (en) * 1987-10-28 1993-01-14 Nippon Shinyaku Co Ltd Fat emulsions as drug carriers
JP2963537B2 (ja) 1989-05-26 1999-10-18 アボツト・ラボラトリーズ クラリトロマイシンの注射用組成物
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
EP0857484A4 (en) * 1995-09-13 2000-12-06 Nippon Shinyaku Co Ltd PGE1- FREEZING DRIED PREPARATION AND METHOD FOR THE PRODUCTION THEREOF
EP0910343A1 (en) * 1996-07-03 1999-04-28 University Of Pittsburgh Emulsion formulations for hydrophilic active agents
AP9901643A0 (en) * 1997-04-28 1999-10-02 Texas Biotechnology Corp Sulfonamides for treatment of endothelin-mediated disorders.
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
JP2003277281A (ja) * 2002-03-20 2003-10-02 Kumamoto Technology & Industry Foundation 静脈炎の予防及び治療のための医薬
US6890558B2 (en) 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
JP4426749B2 (ja) * 2002-07-11 2010-03-03 株式会社産学連携機構九州 Ｏ／ｗ型エマルション製剤
US20050049209A1 (en) * 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
RU2007107359A (ru) * 2004-07-28 2008-09-10 ЭсДи ФАРМАСЬЮТИКАЛЗ, ИНК. (US) Стабильная инъецируемая композиция альфа-токоферилсукцината, его аналогов и солей
CN1634058A (zh) * 2004-10-20 2005-07-06 李晓祥 长春瑞滨乳剂及其制备方法

Also Published As

Publication number Publication date
NO20070785L (no) 2007-04-02
US20060008480A1 (en) 2006-01-12
IL180350A0 (en) 2007-06-03
ECSP077238A (es) 2007-04-26
US20130029918A1 (en) 2013-01-31
HK1100062A1 (en) 2007-09-07
CA2578574A1 (en) 2006-02-16
WO2006017246A3 (en) 2006-03-30
EA012522B1 (ru) 2009-10-30
US20120046310A1 (en) 2012-02-23
CN1859898B (zh) 2011-06-08
MX2007000416A (es) 2007-03-28
ZA200701167B (en) 2010-08-25
KR20070032816A (ko) 2007-03-22
CN1859898A (zh) 2006-11-08
TW200607525A (en) 2006-03-01
RS20070029A (sr) 2008-11-28
CA2578574C (en) 2013-09-10
JP4643641B2 (ja) 2011-03-02
WO2006017246A2 (en) 2006-02-16
US8026250B2 (en) 2011-09-27
JP2008505972A (ja) 2008-02-28
EP1773294A2 (en) 2007-04-18
EP1773294A4 (en) 2012-11-21
AU2005271873A1 (en) 2006-02-16
US20110082168A1 (en) 2011-04-07
BRPI0513178A (pt) 2008-04-29
MA29662B1 (fr) 2008-08-01
US7871632B2 (en) 2011-01-18
US8222268B2 (en) 2012-07-17

Similar Documents

Publication Publication Date Title
EA200700312A1 (ru) Композиции для доставки лекарственных средств с высокой водорастворимостью
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
CY1122336T1 (el) Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις
LTPA2016016I1 (lt) Azetinidai kaip mek inhibitoriai, skirti proliferacinių ligų gydymui
EA200970156A1 (ru) Пиридизиноновые производные
TW200714590A (en) Heterocyclic inhibitors of MEK and methods of use thereof
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
ATE509634T1 (de) Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
SE0301700D0 (sv) Novel compounds
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
EA201270625A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
PE20091562A1 (es) Derivados de naftiridinona como inhibidores de cinasa y composiciones que los comprenden
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
EA201070247A1 (ru) Ингибиторы протеасом
DE602005026556D1 (de) Zusammensetzung zur proteasomhemmung
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
ATE413162T1 (de) Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln
EA201000599A1 (ru) Ингибиторы тирозинкиназы брутона
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
EA200700189A1 (ru) Производные хиназолина в качестве ингибиторов parp
DE602005014382D1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
EA201170441A1 (ru) Терапевтические противовирусные пептиды
BRPI0418330A (pt) composições sólidas de drogas de solubilidade baixa e poloxámeros

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU